Skip to content
DE

NMN as a supplement: what the studies show

Clinical review pending

NMN can raise NAD+ in the blood. What that means for metabolism, physical function and aging, and which questions about effects and safety remain open.

Editorial draft. The medical statements in the source text and the way sources are assigned to them have not yet been independently checked; clinical sign-off is pending.

What nicotinamide mononucleotide is

Nicotinamide mononucleotide (NMN) is a small organic molecule found naturally in every mammalian cell. It is a direct biosynthetic precursor of nicotinamide adenine dinucleotide (NAD+), a helper molecule for hundreds of enzymatic reactions. NAD+ sits at the center of energy metabolism and takes part in processes ranging from making the energy carrier ATP to repairing DNA.

NMN belongs to the pyridine nucleotide family: metabolic intermediates the body makes itself, not vitamins or plant compounds. That changes the question compared with a vitamin supplement. The issue is whether taking this intermediate produces enough NAD+ to make a clinically meaningful difference.

Which family of molecules NMN belongs to

Nicotinamide, nicotinamide riboside (NR), NMN and NAD+ are all structurally related members of the pyridine nucleotide family. NMN consists of a nicotinamide group attached to a ribose sugar that carries a phosphate group. NR is identical except that it lacks this phosphate. The enzyme NMNAT converts NMN directly into NAD+ by adenylylation (a single chemical addition step). The pathway also runs the other way: sirtuins, PARPs and CD38 constantly break down NAD+, releasing nicotinamide, which enters the salvage pathway, a recycling route that builds NAD+ again. Source link

From mouse research to supplement

Mammalian cells make NMN on their own. Commercial NMN is produced by chemical synthesis or enzymatic conversion. It became a target of longevity research after long-term NMN administration in mice blunted age-related declines in insulin sensitivity, blood lipids, eye function and bone density. David Sinclair’s research at Harvard did a lot to draw public attention to it. The decline of NAD+ with age became a central theme in longevity biology, and NMN came to be seen as a practical way to influence that decline. Supplements appeared on the market roughly between 2017 and 2020. In 2022 the FDA took regulatory action. Source link 1 Source link 2

How NMN becomes NAD+

The proposed mechanism is simple: NMN taken by mouth is absorbed, enters cells and is converted there into NAD+ by NMNAT. What is less clear is what happens between swallowing the capsule and that enzymatic step.

The proposed route from NMN to NAD+

NMN serves as a direct substrate for NAD+ biosynthesis via NMNAT. Once NAD+ has been made, it is a substrate for three large enzyme families: sirtuins (SIRT1–7), which regulate gene expression and stress responses; PARPs, which repair damaged DNA; and CD38, which controls inflammatory signaling and calcium balance. All three use up NAD+ in the process. CD38 has been identified as the main driver of the age-related fall in NAD+. Senescent cells, meaning cells that have permanently aged, speed up this fall further by activating CD38-expressing macrophages in aging tissue. The mechanism explains why topping up NAD+ through a precursor is biologically plausible. Whether oral NMN delivers enough NAD+ for clinically relevant effects is something human studies still have to settle. Source link 1 Source link 2 Source link 3

Bioavailability and how NMN is metabolized

The first single-dose pharmacokinetic study in healthy men looked at the safety of oral NMN and documented changes in its breakdown products in the blood. It remains open whether oral NMN is absorbed intact or is first split in the gut into NR or nicotinamide, then absorbed and converted back. The absorption route may not be the most important variable. Oral NMN raises NAD+ in whole blood in a dose-dependent way, and a multicenter dose-response RCT confirmed dose-dependent NAD+ increases at 300, 600 and 900 mg/day. Whatever the exact uptake route, substances that influence NAD+ levels do reach the bloodstream. The oral bioavailability of NMN remains an active research question; that it raises NAD+ in the blood has been shown. Source link 1 Source link 2 Source link 3

What the NMN studies actually show

Claims about NMN supplements fall into four levels of evidence: raising NAD+ in the blood (moderate), metabolic markers such as insulin sensitivity and glucose metabolism (limited), physical function in older adults (limited), and the broader claim of “reversing aging” (anecdotal in humans).

More NAD+ in the blood: moderate evidence

An open-label study showed that oral NMN safely raises NAD+ in whole blood in a dose-dependent way. A multicenter dose-response RCT in healthy middle-aged adults confirmed the same pattern at 300, 600 and 900 mg/day. The finding was also seen in older adults with a pharmaceutical-grade crystalline form (MIB-626). One important caveat: methods for measuring NAD+ are not fully standardized across laboratories, and results vary depending on whether whole blood or peripheral blood mononuclear cells (PBMCs) are measured. Oral NMN is therefore bioavailable enough to shift this surrogate marker measurably. Source link 1 Source link 2 Source link 3

Better metabolic markers: limited evidence

A 10-week RCT in postmenopausal women with prediabetes found that 250 mg/day of NMN improved muscle insulin sensitivity and changed gene expression in muscle. The same dose-response RCT mentioned above showed better 6-minute walk performance but found no change in HOMA-IR compared with placebo. MIB-626 lowered LDL, body weight and diastolic blood pressure in overweight middle-aged adults. Each of these results comes from a single randomized trial in a different group of participants. Independent confirmation is still missing. A meta-analysis of NAD+ precursors found more favorable blood lipid values but inconsistent effects on glucose metabolism. That is a first signal, not yet confirmation. Source link 1 Source link 2 Source link 3 Source link 4

Physical function and walking speed in later life: limited evidence

A 12-week double-blind RCT found that older adults taking NMN maintained their walking speed and slept better. A 12-week RCT in older Japanese adults reported improvements in fatigue, sleep and leg function. A small RCT in amateur runners showed improved aerobic capacity, though the small number of participants limits how far that can be generalized. Studies in this area are mostly small and conducted in Asian populations; confirmation in large multicenter trials is still pending. A 2025 systematic review and meta-analysis found moderate effects on skeletal muscle mass and function in the pooled analysis. Source link 1 Source link 2 Source link 3 Source link 4

Longer life or “reversing aging”: anecdotal human reports

Long-term NMN administration in mice blunted age-related loss of function in several organ systems. These animal data have shaped public attention. No randomized human study has yet examined mortality or biological age over a long enough period and with enough statistical power. A comprehensive review concludes that the mechanism is plausible but the human data are still preliminary. An observational study found that healthy aging and muscle function are linked to NAD+ levels, but correlation is not causation. Source link 1 Source link 2 Source link 3

So far it has not been shown that NMN reverses aging, extends human life in controlled studies, or produces clinically meaningful effects on epigenetic age in long-term studies. There is no FDA-approved use for treating any disease. The 2021 insulin sensitivity finding involved 25 postmenopausal women with prediabetes over 10 weeks. It does not support the general conclusion that NMN treats insulin resistance.

NMN forms and quality markers

NMN is sold as powder or capsules, in standard or microcrystalline form, and for swallowing or for use under the tongue. For the US market, what matters besides the formulation is how the regulatory framework affects product quality.

Standard NMN sold internationally typically comes at 250 to 500 mg per capsule. A microcrystalline NMN polymorph (MIB-626, pharmaceutical grade) produced results on absorption and metabolism and on cardiovascular and metabolic parameters in two studies in 2023. It is the most precisely characterized formulation in the published literature. Sublingual NMN is marketed with claims of better absorption, but few published comparative data on its pharmacokinetics in humans exist. Third-party testing through programs such as USP, NSF or ConsumerLab is limited because NMN is not classified as a dietary supplement in the US. Independent test reports have documented adulteration and deviations from the declared amounts on the commercial market.

Checking a supplier’s certificate of analysis is a sensible minimum step. The NMN market is less regulated than the market for established supplements with a clear US regulatory framework.

US regulatory status of NMN as of May 2026

The regulatory status of NMN in the US differs from that of many established supplements. Under section 201(ff)(3)(B) of the Federal Food, Drug, and Cosmetic Act, a substance that was authorized for investigation as a new drug, and for which substantial clinical investigations were started and made public before it was marketed as a supplement, is excluded from the definition of a dietary supplement. The FDA applied this drug exclusion provision to NMN, citing the status of earlier drug investigations.

In 2022 the FDA issued an NDI response letter to Inner Mongolia Kingdomway Pharmaceutical Co. stating that NMN was excluded from the definition of a dietary supplement under this provision. The Natural Products Association challenged that determination in court. In 2025 the FDA changed its position and issued new letters to ingredient suppliers (including Inner Mongolia Kingdomway and Olympia Health) confirming that NMN is no longer excluded from the definition of a dietary supplement. Since May 2026, NMN can lawfully be marketed as a dietary supplement in the US, subject to the standard NDI notification rules. NMN is not on the World Anti-Doping Agency (WADA) prohibited list.

This section describes the regulatory status and the state of the evidence. It is for information only and is not a recommendation to buy.

Safety, side effects and interactions

Short-term safety in healthy adults is relatively well described at 250 to 900 mg/day for up to 12 weeks. Much less is known about longer periods. Long-term safety data (beyond 12 months, in broader populations) are not yet available in the published literature.

Side effects reported in clinical trials

A 12-week safety study of 250 mg/day in healthy adults found no serious adverse events. The multicenter dose-response RCT of up to 900 mg/day and the MIB-626 studies reported similarly unremarkable safety findings. The adverse events reported across all studies are mild and rare: mild gastrointestinal discomfort, headache and temporary flushing. No controlled long-term safety data covering 12 months exist for any population. NMN has not been studied in pregnancy, during breastfeeding or in children. Source link 1 Source link 2 Source link 3

Possible drug interactions

  • Cancer therapies (theoretical / moderate). NAD+ supports DNA repair through PARPs. Current reviews leave the theoretical interaction with chemotherapy and PARP inhibitors unresolved; PARP and NAD+ biology provides a mechanistic reason for it. Source link 1 Source link 2

  • Insulin and oral glucose-lowering drugs (theoretical/minor). Improved insulin sensitivity was observed in women with prediabetes; in theory this could add to the effect of glucose-lowering treatment. The clinical relevance has not been established. Source link

  • Methylation pathways (theoretical/minor). Nicotinamide derivatives use up methyl groups as they are metabolized. What this means for people taking methylated B vitamins has not been worked out in studies.

There are few data on drug interactions with NMN. Most of the interactions listed are theoretical and have not been documented in clinical trials. A review of NAD+ precursors in aging biology reflects this uncertainty. Anyone taking several medications should discuss NMN before starting with a physician or other clinician who knows their full medication list. Source link

Pregnancy, breastfeeding and special populations

NMN is generally avoided during pregnancy and breastfeeding because there are no controlled human data at supplement doses. Use in people with liver or kidney impairment has not been described in published NMN studies. Use in children has not been characterized either. For people with active or recently treated cancer, the only appropriate route is a decision made with medical supervision, because of the theoretical interaction between raising NAD+, DNA repair and PARP inhibitors. Controlled human data are missing; that does not mean harm has been proven. The uncertainty still matters for clinical decisions.

Who should avoid NMN

Several groups have reasons to avoid NMN. They include pregnant people, people who are breastfeeding, children, and people with active or recently treated cancer. NMN must also not replace medical treatment of a diagnosed metabolic disease.

  • Pregnant or breastfeeding people: no controlled human safety data at supplement doses.

  • Children and adolescents: supplement doses have not been studied in children and adolescents.

  • Active or recently treated cancer: theoretical NAD+/DNA repair interaction with chemotherapy and PARP inhibitors; clearance from the oncology team is required.

  • People following protocols that affect methylation: theoretical use of methyl groups. The clinical relevance is unclear, but it should be discussed with a doctor.

  • Anyone whose underlying concern is treating a diagnosed metabolic disease: clinical care, not taking supplements, is the right path.

If any of these points applies, NMN should only be started after discussing it with a physician or other clinician who knows the person’s medications and lab results.

NMN vs. NR: where they differ

NMN and nicotinamide riboside (NR) are the two best-studied NAD+ precursors. Their biochemistry, evidence base and regulatory situation differ enough to make a careful comparison worthwhile.

  • Source / chemistry. NMN: nicotinamide mononucleotide; one biosynthetic step to NAD+. NR: nicotinamide riboside; two biosynthetic steps to NAD+ (NR → NMN → NAD+).

  • Bioavailability. NMN: raises NAD+ in whole blood in human studies, dose-dependently at 300–900 mg/day. NR: a 2025 review found that NR and NMN have only moderate effects on muscle mass and function in older adults. Source link 1 Source link 2 Source link 3

  • Strongest human evidence. NMN: a 2021 RCT in 25 postmenopausal women with prediabetes over 10 weeks showed improved muscle insulin sensitivity. NR: several phase 2 RCTs in older adults with cardiometabolic surrogate endpoints. Source link

  • Dose range studied. NMN: 250–900 mg/day in human RCTs. NR: 250–1,000 mg/day in human RCTs.

  • Key safety differences. NMN: mild gastrointestinal discomfort, headache and flushing reported in studies. NR: similar profile; longer experience with safety at supplement doses because it reached the US market earlier.

  • Cost (relative). NMN: $$–$$$. NR: $$.

  • Regulatory status. NMN: a turbulent history. The FDA’s 2022 drug exclusion decision was reversed in 2025; since May 2026, NMN can lawfully be marketed as a US dietary supplement, subject to the standard NDI notification rules. NR: lawfully marketed as a dietary supplement in the US since 2016.

For someone mainly interested in the most frequently cited NMN study on a clinically meaningful metabolic endpoint, the 2021 postmenopausal prediabetes study (N=25, 10 weeks) is the relevant reference. For someone mainly interested in a substance with a clear US regulatory path, NR is the relevant comparison. Both raise NAD+ in the blood at comparable doses; the pooled evidence for effects on muscle is limited for both. For individual assessment, the source text names changes in HbA1c, fasting insulin and hs-CRP after 12 weeks, measured before and after starting in the same lab under the same morning conditions. Source link

What to measure before and after 12 weeks

How you feel after starting is not a reliable yardstick on its own. The source text describes a lab comparison between day 0 and week 12, under the same morning conditions in the same lab, as the only way to tell a real response apart from placebo effects or from fluctuating values drifting back toward their average (regression to the mean).

  • Whole-blood NAD+: the surrogate marker that changed in the studies (multicenter dose-response RCT; open-label dose finding). Availability and standardization vary by lab. When ordering the test, clarify exactly which substance is measured and by which method. Source link 1 Source link 2

  • HbA1c: average blood sugar over three months; the metabolic endpoint considered in the 2021 postmenopausal study and the 2023 MIB-626 study. Source link 1 Source link 2

  • Fasting insulin: meant to reflect insulin sensitivity directly. HOMA-IR is calculated from fasting glucose and fasting insulin together: the surrogate marker of the 2021 prediabetes study. Source link

  • hs-CRP: picks up low-grade inflammation in the body. The NAD+, CD38 and sirtuin axis is directly linked to inflammatory signaling pathways.

  • IGF-1: captures aspects of the growth hormone and longevity axis and is named as context for trials of supplements of this kind.

Baseline values taken before starting a supplement give objective reference points for later changes. Without them, a response cannot be told apart from placebo effects or from fluctuating values drifting back toward their average.

When a medical workup should come first

Fatigue, cognitive complaints, weight gain and the general feeling of “aging faster than expected” should be checked by a doctor. Metabolic and inflammatory testing in primary care (including a thyroid test and a sleep assessment) is the right starting point, not a longevity supplement. Before taking NMN, it should be clear what is causing these complaints. The objective starting point is a blood test: metabolic and inflammatory markers measured before any intervention begins.

In a loosely regulated market with many competing vendors, measured baseline values are the most reliable basis for judging an NMN regimen later on.

Frequently asked questions

What is an NMN supplement?

NMN (nicotinamide mononucleotide) is a small organic molecule and a direct biosynthetic precursor of NAD+, a cofactor needed for hundreds of enzyme reactions in cells. In biosynthesis it sits one step closer to NAD+ than nicotinamide riboside (NR) does, which makes it a more direct route to this essential molecule.

What are NMN supplements used for?

NMN has mainly been studied for age-related metabolic outcomes. Research in postmenopausal women with prediabetes observed improved muscle insulin sensitivity with 250 mg/day over 10 weeks, while dose-response studies have shown associations with better performance on the 6-minute walk test (HOMA-IR did not differ from placebo). Source link 1 Source link 2

What does an NMN supplement do in the body?

NMN is converted into NAD+ by the enzyme NMNAT. NAD+ is needed by sirtuins, PARPs and CD38, three enzyme families involved in DNA repair, gene expression and inflammatory signaling. While the biochemistry of how NMN raises NAD+ is well characterized, the evidence for clinical outcomes in humans remains limited. Source link 1 Source link 2

Is NMN a vitamin, mineral or plant compound?

NMN is not a vitamin, a mineral or a plant compound. It is a pyridine nucleotide, an endogenous metabolic intermediate that the body makes from nicotinamide (a form of B3). It is sold as a dietary supplement. The FDA’s 2022 drug exclusion decision on NMN was reversed in 2025, and as of May 2026 NMN can lawfully be marketed as a US dietary supplement, subject to the standard NDI notification rules.

Where do NMN supplements come from?

Mammalian cells make NMN naturally from nicotinamide through the salvage pathway. Commercial NMN supplements are produced by chemical synthesis or by enzymatic conversion in industrial fermentation. Foods such as broccoli, avocado and edamame naturally contain traces of it, but these amounts are far below the doses used in human studies (250–900 mg/day).

Are there alternatives to NMN supplements?

Yes. NMN sits one biosynthetic step closer to NAD+ than NR (nicotinamide riboside): NR → NMN → NAD+. A 2025 systematic review and meta-analysis found that, at comparable doses, NR and NMN have only moderate effects on muscle mass and function in older adults. Both have been sold lawfully as dietary supplements in the US since May 2026. NMN’s regulatory history is more turbulent (the FDA’s 2022 drug exclusion decision was reversed in 2025 after a lawsuit), while NR has had a stable supplement pathway since 2016. Source link

What side effects do NMN supplements have?

The side effects reported most often in studies are mild and rare, including gastrointestinal discomfort, headache and temporary flushing. There are no controlled human safety data for pregnancy or breastfeeding, and NMN has not been characterized in children. Drug interactions have so far been little studied, although there are theoretical concerns about interactions with cancer therapies, given the role of NAD+ in DNA repair. Source link 1 Source link 2

Which blood tests does the source text name before starting?

It names whole-blood NAD+ where available, HbA1c, fasting insulin, hs-CRP and IGF-1 as baseline values. Comparing HbA1c, fasting insulin and hs-CRP before starting and 12 weeks later provides data on possible metabolic changes. The source text gives this approach more weight than the subjective feeling of having more energy, especially for metabolic goals.

Sources and literature from the source text

  • Yoshino J, Baur JA, Imai SI (2018). NAD. Cell metabolism, 27(3), 513-528. https://doi.org/10.1016/j.cmet.2017.11.002

  • Mills KF, Yoshida S, Stein LR, Grozio A, Kubota S, Sasaki Y, Redpath P, Migaud ME, Apte RS, Uchida K, Yoshino J, Imai SI (2016). Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice. Cell metabolism, 24(6), 795-806. https://doi.org/10.1016/j.cmet.2016.09.013

  • Katsyuba E, Romani M, Hofer D, Auwerx J (2020). NAD. Nature metabolism, 2(1), 9-31. https://doi.org/10.1038/s42255-019-0161-5

  • Camacho-Pereira J, Tarragó MG, Chini CCS, Nin V, Escande C, Warner GM, Puranik AS, Schoon RA, Reid JM, Galina A, Chini EN (2016). CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. Cell metabolism, 23(6), 1127-1139. https://doi.org/10.1016/j.cmet.2016.05.006

  • Covarrubias AJ, Kale A, Perrone R, Lopez-Dominguez JA, Pisco AO, Kasler HG, Schmidt MS, Heckenbach I, Kwok R, Wiley CD, Wong HS, Gibbs E, Iyer SS, Basisty N, Wu Q, Kim IJ, Silva E, Vitangcol K, Shin KO, … Verdin E (2020). Senescent cells promote tissue NAD. Nature metabolism, 2(11), 1265-1283. https://doi.org/10.1038/s42255-020-00305-3

  • Irie J, Inagaki E, Fujita M, Nakaya H, Mitsuishi M, Yamaguchi S, Yamashita K, Shigaki S, Ono T, Yukioka H, Okano H, Nabeshima YI, Imai SI, Yasui M, Tsubota K, Itoh H (2020). Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. Endocrine journal, 67(2), 153-160. https://doi.org/10.1507/endocrj.EJ19-0313

  • Okabe K, Yaku K, Uchida Y, Fukamizu Y, Sato T, Sakurai T, Tobe K, Nakagawa T (2022). Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects. Frontiers in nutrition, 9, 868640. https://doi.org/10.3389/fnut.2022.868640

  • Yi L, Maier AB, Tao R, Lin Z, Vaidya A, Pendse S, Thasma S, Andhalkar N, Avhad G, Kumbhar V (2023). The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience, 45(1), 29-43. https://doi.org/10.1007/s11357-022-00705-1

  • Pencina KM, Lavu S, Dos Santos M, Beleva YM, Cheng M, Livingston D, Bhasin S (2023). MIB-626, an Oral Formulation of a Microcrystalline Unique Polymorph of β-Nicotinamide Mononucleotide, Increases Circulating Nicotinamide Adenine Dinucleotide and its Metabolome in Middle-Aged and Older Adults. The journals of gerontology. Series A, Biological sciences and medical sciences, 78(1), 90-96. https://doi.org/10.1093/gerona/glac049

  • Yoshino M, Yoshino J, Kayser BD, Patti GJ, Franczyk MP, Mills KF, Sindelar M, Pietka T, Patterson BW, Imai SI, Klein S (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science (New York, N.Y.), 372(6547), 1224-1229. https://doi.org/10.1126/science.abe9985

  • Pencina KM, Valderrabano R, Wipper B, Orkaby AR, Reid KF, Storer T, Lin AP, Merugumala S, Wilson L, Latham N, Ghattas-Puylara C, Ozimek NE, Cheng M, Bhargava A, Memish-Beleva Y, Lawney B, Lavu S, Swain PM, Apte RS, … Bhasin S (2023). Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study. The Journal of clinical endocrinology and metabolism, 108(8), 1968-1980. https://doi.org/10.1210/clinem/dgad027

  • Zhong O, Wang J, Tan Y, Lei X, Tang Z (2022). Effects of NAD+ precursor supplementation on glucose and lipid metabolism in humans: a meta-analysis. Nutrition & metabolism, 19(1), 20. https://doi.org/10.1186/s12986-022-00653-9

  • Morifuji M, Higashi S, Ebihara S, Nagata M (2024). Ingestion of β-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults in a double-blind randomized, placebo-controlled study. GeroScience, 46(5), 4671-4688. https://doi.org/10.1007/s11357-024-01204-1

  • Peluso A, Damgaard MV, Mori MAS, Treebak JT (2021). Age-Dependent Decline of NAD. Nutrients, 14(1). https://doi.org/10.3390/nu14010101

  • Liao B, Zhao Y, Wang D, Zhang X, Hao X, Hu M (2021). Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study. Journal of the International Society of Sports Nutrition, 18(1), 54. https://doi.org/10.1186/s12970-021-00442-4

  • Prokopidis K, Moriarty F, Bahat G, McLean J, Church DD, Patel HP (2025). The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis. Journal of cachexia, sarcopenia and muscle, 16(3), e13799. https://doi.org/10.1002/jcsm.13799

  • Bhasin S, Seals D, Migaud M, Musi N, Baur JA (2023). Nicotinamide Adenine Dinucleotide in Aging Biology: Potential Applications and Many Unknowns. Endocrine reviews, 44(6), 1047-1073. https://doi.org/10.1210/endrev/bnad019

  • Janssens GE, Grevendonk L, Perez RZ, Schomakers BV, de Vogel-van den Bosch J, Geurts JMW, van Weeghel M, Schrauwen P, Houtkooper RH, Hoeks J (2022). Healthy aging and muscle function are positively associated with NAD. Nature aging, 2(3), 254-263. https://doi.org/10.1038/s43587-022-00174-3

  • Fukamizu Y, Uchida Y, Shigekawa A, Sato T, Kosaka H, Sakurai T (2022). Safety evaluation of β-nicotinamide mononucleotide oral administration in healthy adult men and women. Scientific reports, 12(1), 14442. https://doi.org/10.1038/s41598-022-18272-y

  • Montllor-Albalate C, Song Z, Chen D (2021). The therapeutic promises of NAD. Cell metabolism, 33(7), 1274-1275. https://doi.org/10.1016/j.cmet.2021.06.008

Origin and editorial review status

Translated and prepared for Nutrient Desk from the source article. Promotional membership, newsletter and lab offers were removed. The bibliography is kept in its original form so each entry can be identified unambiguously. Figures and source references were carried over; which piece of evidence supports which individual statement must be checked before publication. This draft is not cleared for indexing.